ArticleInternational journal of epidemiology2026
A countrywide study on post-COVID-19 condition in Brazil: the Epicovid 2.0.
Article in International journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Patterns of medication use among individuals with Covid-19 in Brazil: Epicovid 2.0.Revista de saude publica · 2026Article
- Social long COVID: impacts of the COVID-19 pandemic on public health and policy in Brazil.International journal of epidemiology · 2026Article
- EPICOVID-19 and EPICOVID 2.0: building knowledge on COVID-19 epidemiology during the pandemic in Brazil.International journal of epidemiology · 2026Article
- COVID-19: lessons from Brazil.International journal of epidemiology · 2026Article
- Using an epidemiological lens to evaluate the impacts of COVID-19 in Brazil.International journal of epidemiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe COVID-19 pandemic had severe impacts worldwide. We assessed the occurrence of a post-COVID-19 condition (PCC) in Brazil and described the persistence of symptoms 4 years after the start of the pandemic.
methodsA population-based survey was carried out in 133 large cities in 2024. The current prevalence of 21 COVID-19-related symptoms was recorded for all respondents, regardless of infection history. The World Health Organization's definition of PCC was adopted. Results were described by country region and socio-demographic characteristics.
resultsOf the 33 250 individuals sampled, 28.6% [95% confidence interval (CI) 27.3 to 30.0] reported having had COVID-19, of whom 65.1% (95% CI 62.7 to 67.4) fulfilled the criteria for PCC at any time in the past. Prevalence of PCC was highest among those who were hospitalized and needed intubation or oxygen support [85.3% (95% CI 79.6 to 89.7)]. The average number of current symptoms among those with PCC was 7.21 (95% CI 6.73 to 7.69) compared with 2.77 (95% CI 2.62 to 2.92) among those without a COVID-19 history. The most common symptoms for those with COVID-19 history were memory loss, anosmia, loss of sensitivity in the hands, difficulty in concentration, and hair loss. Women and Indigenous individuals presented a higher average number of symptoms compared with those without a history.
conclusionA high proportion of individuals who suffered from COVID-19 presented symptoms 4 years after the SARS-CoV-2 emergence; almost two-thirds presented PCC. Population-based studies in different countries are necessary to better understand the epidemiology of this serious condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.